ExalysExalysExalysExalysExalysExalys
  • Home
  • Company
  • Therapeutic Approach
  • News
  • Contact Us
    • English
  • Home
  • Company
  • Therapeutic Approach
  • News
  • Contact Us

Search

  • TARGETED ANTI-INFLAMMATORY THERAPEUTICS
    BIOMARKER-SUPPORTED APPROACHES TO ADDRESS UNMET NEEDS

Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options.

Exalys is initially targeting postoperative delirium, the most common complication of surgery in older patients and a key driver of poor health outcomes.

The Exalys portfolio of product candidates has the potential to be applied to a number of other acute and chronic disease states with high societal impacts.

       
      • Home
      • Company
      • Therapeutic Approach
      • Contact
      • News
      • Terms and Conditions
      • Privacy Policy